Antibacterial activity of quinuprisitin/dalfopristin on the clinical isolates of Enterococcus faecium in vitro
10.13699/j.cnki.1001-6821.2016.12.024
- VernacularTitle:奎奴普丁／达福普汀对屎肠球菌临床分离株的体外抗菌活性分析
- Author:
Huan-Le LIU
1
;
Xiao-Le WU
;
Chun-Chan LIN
;
Shu-Ying CHEN
;
Xue-Qing ZHANG
;
Fang-You YU
Author Information
1. 温州医科大学 附属第一医院 检验科
- Keywords:
Enterococcus faecium;
quinuprisitin/dalfopristin;
resistance
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(12):1136-1137,1141
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the antibacterial activity of quinu-prisitin/dalfopristin on the clinical isolates of Enterococcus faecium in vitro.Methods A total of 2217 Enterococcus faecium isolates were isola-ted from the various specimens of patients at the first affiliated hospital of Wenzhou medical university from January , 2011 to December , 2015.The susceptibility of 2217 Enterococcus faecium isolates to quinuprisitin/dalfopristin and the susceptibility of quinuprisitin/dalfopristin -non -susceptible isolates to clinically often used antimicrobials were determined by full automated Microbiology Analyzer.Results Among 2217 Entero-coccus faecium isolates, 115 (5.2%) were non -susceptible to quinu-prisitin/dalfopristin, among which 25 with quinuprisitin/dalfopristin re-sistance and 90 with quinuprisitin/dalfopristin intermediate.The rates of quinuprisitin/dalfopristin non -susceptibility among tested clinical iso-lates from 2011 to 2015 were 4.3%(25/588), 3.1%(18/581), 6.2%(22/353), 6.3%( 25/394 ) and 8.3%( 25/301 ), respectively.All non-susceptible isolates were susceptible to vancomycin , linezolid , teicoplanin and tigecycline.However , more than 80% of theses isolates were resistant to ampicllin, penicillin, levofloxacin, ciprofloxacin, moxifloxacin and erythromycin.Conclusion Quinuprisitin/dalfopristin has good antimicrobial activity in vitro against Enterococcus faecium clinical isolates.The prevalence of quinuprisitin/dalfopristin resistance remained relatively stable and low , but non-susceptible rate showed an upward trend.
